Free Trial

PMV Pharmaceuticals Q1 2024 Earnings Report

PMV Pharmaceuticals logo
$1.50 0.00 (0.00%)
(As of 12/20/2024 05:30 PM ET)

PMV Pharmaceuticals EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.35
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

PMV Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PMV Pharmaceuticals Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

This Indicator called BOTH NVDA rallies (Ad)

Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is…

Click this link here. 

PMV Pharmaceuticals Earnings Headlines

PMV Pharmaceuticals files $200M mixed securities shelf
PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
Could This Tiny Device Help You Make an Extra $30k a Year?
I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results
Oppenheimer Sticks to Its Hold Rating for PMV Pharmaceuticals (PMVP)
PMV Pharmaceuticals (PMVP) Gets a Buy from Craig-Hallum
See More PMV Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PMV Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMV Pharmaceuticals and other key companies, straight to your email.

About PMV Pharmaceuticals

PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

View PMV Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings